204 related articles for article (PubMed ID: 26459662)
1. New levodopa therapeutic strategies.
LeWitt PA
Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S37-40. PubMed ID: 26459662
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
[TBL] [Abstract][Full Text] [Related]
3. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
[TBL] [Abstract][Full Text] [Related]
4. Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication.
Salomone G; Marano M; di Biase L; Melgari JM; Di Lazzaro V
Parkinsonism Relat Disord; 2015 Sep; 21(9):1124-5. PubMed ID: 26242552
[No Abstract] [Full Text] [Related]
5. Novel formulations and modes of delivery of levodopa.
Poewe W; Antonini A
Mov Disord; 2015 Jan; 30(1):114-20. PubMed ID: 25476691
[TBL] [Abstract][Full Text] [Related]
6. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.
Nyholm D; Askmark H; Gomes-Trolin C; Knutson T; Lennernäs H; Nyström C; Aquilonius SM
Clin Neuropharmacol; 2003; 26(3):156-63. PubMed ID: 12782919
[TBL] [Abstract][Full Text] [Related]
7. [Optimisation of treatment of Parkinson's disease with levodopa].
Białecka M; Adamiak U; Gawrońska-Szklarz B
Neurol Neurochir Pol; 2009; 43(5):446-59. PubMed ID: 20054747
[TBL] [Abstract][Full Text] [Related]
8. Levodopa delivery systems: advancements in delivery of the gold standard.
Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
[TBL] [Abstract][Full Text] [Related]
9. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Metman LV; Hoff J; Mouradian MM; Chase TN
Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
[TBL] [Abstract][Full Text] [Related]
10. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
Harder S; Baas H; Rietbrock S
Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients.
Senek M; Nyholm D; Nielsen EI
Eur J Clin Pharmacol; 2018 Oct; 74(10):1299-1307. PubMed ID: 29882153
[TBL] [Abstract][Full Text] [Related]
12. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Deleu D; Jacques M; Michotte Y; Ebinger G
Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic optimisation in the treatment of Parkinson's disease.
Contin M; Riva R; Albani F; Baruzzi A
Clin Pharmacokinet; 1996 Jun; 30(6):463-81. PubMed ID: 8792058
[TBL] [Abstract][Full Text] [Related]
14. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
LeWitt PA
Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198
[TBL] [Abstract][Full Text] [Related]
15. New drug delivery strategies for improved Parkinson's disease therapy.
Di Stefano A; Sozio P; Iannitelli A; Cerasa LS
Expert Opin Drug Deliv; 2009 Apr; 6(4):389-404. PubMed ID: 19382882
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion.
Westin J; Nyholm D; Pålhagen S; Willows T; Groth T; Dougherty M; Karlsson MO
Clin Neuropharmacol; 2011; 34(2):61-5. PubMed ID: 21297456
[TBL] [Abstract][Full Text] [Related]
17. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
[TBL] [Abstract][Full Text] [Related]
18. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
[TBL] [Abstract][Full Text] [Related]
20. New treatments for the motor symptoms of Parkinson's disease.
Vijverman AC; Fox SH
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
